Navigation Links
In vitro antibody production enables HIV infection detection in window period -- key to safer blood
Date:7/24/2009

This release is available in Chinese.

Researchers in Israel and Kenya have shown that the contribution of variable degrees of immune suppression, either due to existing chronic infections such as parasitemias and/or nutrition, in different populations may influence and prolong the serological-diagnostic window period of HIV. However, the immunosuppression can be overcome, by in-vitro enhancement of antibody production (termed- Stimmunology). The results, which appear in the August 2009 issue of Experimental Biology and Medicine, show that pre-treating the whole blood sample in the SMARTube containing immune potentiating agents promoted the synthesis and release of antibodies against HIV-1 prior to their detection in corresponding plasma samples in a group of donors who would otherwise be classified as HIV-1 seronegative blood donors. The identification of techniques that can lead to detection of HIV infection during this window period is of obvious public health importance especially in resource poor settings highlighting the importance of these findings. Overcoming the suppression, in-vitro, led to the production of detectable levels of anti-HIV antibodies in the whole blood sample and to the detection of potentially infectious blood units which were missed by regular HIV serology. Interestingly, the ratio of missed infections among the total HIV infected blood donors was higher among the younger (high-school) donors versus adult donors.

The research team, Dr. Jasper Mumo, immunologist from the Department of Human Pathology, University of Nairobi, Kenya, Dr. Ami Vansover, head of the Virology Laboratory, Public Health Laboratories, Ministry of Health, Israel, and Dr. Tamar Jehuda-Cohen, an immunologist, Faculty of Biomedical Engineering, Technion-Israel Institute of Technology, ran the same HIV antibody tests using both regular plasma and SMART-plasma (plasma after the Stimmunology step) from blood donors in Kenyata hospital. Dr. Jehuda-Cohen noted that "this study, offers one of the keys to making the blood supply safer, by overcoming the problem of this protracted window period perhaps unique to certain field study sites with a high incidence/prevalence of HIV-1. This is true not only for HIV but also for other infections such as HCV, which has even a longer window period than HIV"

In summary, in-vitro enhancement of antibody production, made simple by the SMARTube, has been shown to enable the earlier detection of HIV infection. This is critical for saving lives not only via a safer blood supply but also by detection of HIV infection among pregnant women who seem to have a very long window period. "A pregnant women testing false negative for HIV will not be offered ART which could have saved her baby" said Dr. Jehuda-Cohen (a mother of seven).

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "The article by Mumo and colleagues may lead to a change in testing paradigms and algorithms in HIV and other infections with a diagnostic window period."


'/>"/>

Contact: Tamar Jehuda Cohen
tamarjc@tx.technion.ac.il
972-545-200-476
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Combined stem cell-gene therapy approach cures human genetic disease in vitro
2. In-vitro fertilization improved with 3-D/4-D-guided embryo transfer and new placement target
3. NEWSLETTER: Antibody Fragment Production Breakthrough with 2nd Generation EBA
4. Novel antibody prevents infection by hepatitis C virus
5. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
6. Antibody key to treating variant CJD, scientists find
7. UC San Diego and Genentech scientists develop potentially disruptive antibody sequencing technology
8. ETH Zurich researchers develop antibody test
9. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
10. Yale chemist receives NIH Young Investigator Award for antibody targeting
11. Reversing cognitive deficits: Injectable antibody may attack source of problem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology: